Travel Medicine and Infectious Disease RSS feed: Current Issue. The journal will publish original papers and invited reviews covering all aspects of travel medicine and infectious disease. These will include the epidemiology and surveillance of travel-related infectious disease, vaccine-preventable disease, illness in returning travellers, aviation medicine including psychological aspects, environmental hazards of travel, practical clinical issues for travellers, tropical medicine and tropical skin disease and general aspects of travel medicine and infectious disease. The journal will also bring together knowledge from different specialties involved in the research and clinical practice of travel medicine and infectious disease. The journal will publish topical leading academic reviews and opinion papers, original articles and case reports as well as a correspondence section. http://www.travelmedicinejournal.com/?rss=yesElsevier Inc.en © 2012 Published by Elsevier Inc. All rights reserved. Travel Medicine and Infectious Disease1477-8939102March 2012 © 2012 Published by Elsevier Inc. All rights reserved. healthpermissions@elsevier.comhttp://www.travelmedicinejournal.com/article/PIIS1477893912000464/abstract?rss=yesEditorial board10.1016/S1477-8939(12)00046-4Travel Medicine and Infectious Disease 10, 2 (2012)2012-03-01Travel Medicine and Infectious Disease2012-03-01102S1477-8939(12)X0003-6iihttp://www.travelmedicinejournal.com/article/PIIS1477893912000245/abstract?rss=yesA long held aspiration of mine since founding the Journal of Travel Medicine and Infectious Disease (TMAID) was to establish close collaborative affiliations with Travel Medicine societies, an important way of furthering the development of travel medicine as a specialty. It is particularly gratifying to have achieved this not only with the Faculty of Travel Medicine (FTM) of the Royal College of Physicians and Surgeons of Glasgow (RCPSG), but now also with a newly evolving travel medicine society in Latin America. This editorial written together with Alfonso J. Rodriguez-Morales of Latin American Society for Travel Medicine, is an appropriate mark of this occasion.Extending across continents: Travel medicine and Latin AmericaAlfonso J. Rodriguez-Morales, Jane N. Zuckerman10.1016/j.tmaid.2012.02.002Travel Medicine and Infectious Disease 10, 2 (2012)2012-03-27Travel Medicine and Infectious Disease2012-03-27102S1477-8939(12)X0003-6Editorial5556http://www.travelmedicinejournal.com/article/PIIS1477893912000038/abstract?rss=yesThe history of immunisation provides many inspiring examples of pioneers advancing boldly the rigour of the scientific method while innovating with vaccine protection. Two noteworthy examples are Louis Pasteur’s administration of rabies vaccine to Joseph Meister on 6 July 1885 and Edward Jenner’s inoculation of James Phipps with material from Sarah Nelm’s cowpox lesion on 14 May 1796. These brilliancies in the history of medicine and public health offer compelling lessons for those concerned about ensuring that immunisation practice is evidence-based.Ensuring that human rights and appropriate evidence endure as immunisation cornerstonesDavid N. Durrheim10.1016/j.tmaid.2012.01.002Travel Medicine and Infectious Disease 10, 2 (2012)2012-02-06Travel Medicine and Infectious Disease2012-02-06102S1477-8939(12)X0003-6Editorial5758http://www.travelmedicinejournal.com/article/PIIS1477893912000294/abstract?rss=yesSummary: Financially comfortable, with ample spare time and much better health, older people travel more than ever and to more adventurous destinations. Taking Australian senior adventure travellers to Peru as an example, travel health preparations need to take into account the phenomenon ‘senior traveller’, the destination with its attractions and challenges, and age-related changes and restrictions. The need for routine travel health advice, vaccinations and prophylaxis remains unchanged. However, more emphasis should be placed on locality-specific issues so that age-appropriate advice and preparations maximize the chances for a safe and memorable travel experience.Australian senior adventure travellers to Peru: Maximising older tourists’ travel health experienceIrmgard Bauer10.1016/j.tmaid.2012.03.002Travel Medicine and Infectious Disease 10, 2 (2012)2012-03-29Travel Medicine and Infectious Disease2012-03-29102S1477-8939(12)X0003-6Review5968http://www.travelmedicinejournal.com/article/PIIS147789391200004X/abstract?rss=yesSummary: The recognition that viruses related to rabies virus cause rabies in humans has stimulated research into the relationships, geographic distribution and natural histories of these viruses. This paper reviews what is known of these fascinating viruses and the complexity of prevention and treatment of the disease they cause.The other rabies viruses: The emergence and importance of lyssaviruses from bats and other vertebratesCharles H. Calisher, James A. Ellison10.1016/j.tmaid.2012.01.003Travel Medicine and Infectious Disease 10, 2 (2012)2012-03-02Travel Medicine and Infectious Disease2012-03-02102S1477-8939(12)X0003-6Original Articles6979http://www.travelmedicinejournal.com/article/PIIS1477893912000257/abstract?rss=yesSummary: Hepatitis E virus (HEV), a causative agent of human hepatitis E, is transmitted through an oral-fecal route, often by contaminated drinking water. Serum specimens were collected from 112 non-A, -B, and –C acute hepatitis patients from 1989 to 2004 in Japan. Of these, 24 patients were found to be positive for anti-HEV IgM and diagnosed with acute Hepatitis E. Seventeen of these patients had a clear history of traveling abroad before disease onset and were counted as cases of imported HEV infection. HEV RNA was detected in 16 of these imported cases, and the nucleotide sequences similar to those of HEV detected in India, Bangladesh, and China were identified. By phylogenetic analysis, the remaining imported case appeared to have been imported from India, even though the patient's travel history was uncertain. These results indicated that some sporadic cases of hepatitis E in Japan are caused by imported HEV, and that phylogenetic analyses enable us to identify the country or area where a patient has been infected.A retrospective study on imported hepatitis E in JapanTian-Cheng Li, Susumu Ochiai, Hiroaki Ishiko, Takaji Wakita, Tatsuo Miyamura, Naokazu Takeda10.1016/j.tmaid.2012.02.003Travel Medicine and Infectious Disease 10, 2 (2012)2012-03-09Travel Medicine and Infectious Disease2012-03-09102S1477-8939(12)X0003-6Original Articles8085http://www.travelmedicinejournal.com/article/PIIS1477893912000270/abstract?rss=yesSummary: Malaria and dengue are important problems in Japan particularly since international travel to developing countries has become increasingly popular. To describe the clinical features of malaria and dengue cases in Japan, a retrospective study was conducted on 50 malaria cases and 40 dengue cases presented to the National Centre for Global Health and Medicine of Japan between 2005 and 2010. The most frequent area of acquisition for cases of malaria was Africa (76.0%), and for dengue fever was Asia (90.0%). Although the immigrant population is very small in Japan, patients categorized as visiting friends and relatives were relatively high in proportion, which is similar to Western reports. Confirmed cases of malaria and dengue account for less than 10% of the all travelers returning with any health problems according to the National Centre for Global Health and Medicine. Careful observation of symptoms and signs helps the differential diagnosis of malaria and dengue.Imported malaria and dengue fever in returned travelers in Japan from 2005 to 2010Yasutaka Mizuno, Yasuyuki Kato, Shigeyuki Kano, Tomohiko Takasaki10.1016/j.tmaid.2012.02.005Travel Medicine and Infectious Disease 10, 2 (2012)2012-03-19Travel Medicine and Infectious Disease2012-03-19102S1477-8939(12)X0003-6Original Articles8691http://www.travelmedicinejournal.com/article/PIIS1477893912000063/abstract?rss=yesSummary: The World Health Organisation (WHO) estimated that in 2002, 1.3 million people were blind due to trachoma, an eye infection caused by Chlamydia trachomatis. This review examines the evidence behind current strategies to reduce the global burden of trachoma. Trachoma disappeared from most western nations before the advent of antibiotics, probably due to improvements in water, sanitation and hygiene. The current effort to target trachoma, headed by the WHO and the Alliance for the Global Elimination of Trachoma by 2020, is called the SAFE (Surgery, Antibiotics, Facial cleanliness and Environmental improvement) strategy. Surgery for trachoma is more cost effective than extra-capsular cataract surgery and can reverse trichiasis (in-growing eyelashes), but needs to be repeated every few years. A single oral dose of azithromycin can eliminate trachoma infection, but cannot be used in infants under 6 months old, and needs to be given every few years in communities with a high prevalence of disease. Improved health education and facial hygiene has been linked to a lower incidence of trachoma, but the evidence is less clear than for surgery and antibiotics. Pit latrines and spraying with permethrin insecticide may reduce the spread of trachoma via eye-seeking flies.Review: Targeting trachoma: Strategies to reduce the leading infectious cause of blindnessAlex Baneke10.1016/j.tmaid.2012.01.005Travel Medicine and Infectious Disease 10, 2 (2012)2012-02-10Travel Medicine and Infectious Disease2012-02-10102S1477-8939(12)X0003-6First Look - Student Research9296http://www.travelmedicinejournal.com/article/PIIS1477893912000051/abstract?rss=yesSummary: Leishmaniasis is a parasitic infection caused by the obligate intracellular protazoa leishmania. The most commonly encountered form is cutaneous leishmaniasis (CL), which generally manifests as a chronic, painless ulcer. Recent increases in the incidence of CL worldwide due in large part to increased immigration and international travel, combined often with the lack of familiarity with the disease in non-endemic settings, pose the continued problems of delayed diagnosis and inappropriate treatment. A case is described of imported cutaneous leishmaniasis occurring in a 48 year-old male who presented with multiple painless, progressively ulcerating lesions after returning from a one week trip to Bandiagara, Mali, West Africa. After four months of misdiagnoses and ineffective treatments, he was referred to a tropical disease specialist where the diagnosis was made with a skin biopsy followed by a tissue impression smear, culture and PCR. Appropriate treatment was initiated and the lesions resolved with minimal scarring. The goals of this case report are threefold: first, to stress the importance of associating chronic ulcers in a traveler with potential cutaneous leishmaniasis; second, to emphasize the clinical utility of PCR for the diagnosis; and third, to discuss the clinical approach to treatment.Imported cutaneous leishmaniasis in a short-term traveler returning from Central Mali – The role of PCRPatrick Kelly, Thomas Baudry, François Peyron10.1016/j.tmaid.2012.01.004Travel Medicine and Infectious Disease 10, 2 (2012)2012-03-09Travel Medicine and Infectious Disease2012-03-09102S1477-8939(12)X0003-6Short Communications97100http://www.travelmedicinejournal.com/article/PIIS1477893912000269/abstract?rss=yesSummary: Lactococcus garvieae is a rare but emerging human pathogen causing a variety of infections with only ten cases of infective endocarditis reported in the literature. We present the only case of Lactococcus garvieae infective endocarditis affecting both a native and a bioprosthetic valve in a traveler returning from rural South Korea.Lactococcus garvieae multi-valve infective endocarditis in a traveler returning from South KoreaHolly Fleming, Star V. Fowler, Luong Nguyen, Diedre M. Hofinger10.1016/j.tmaid.2012.02.004Travel Medicine and Infectious Disease 10, 2 (2012)2012-03-09Travel Medicine and Infectious Disease2012-03-09102S1477-8939(12)X0003-6Short Communications101104http://www.travelmedicinejournal.com/article/PIIS1477893912000233/abstract?rss=yesThe ascendency of smart phones and devices has seen a rapidly expanding array of applications or “apps” to service this burgeoning market. These applications include those directed at travellers. Globally, there are few applications directed specifically at travellers’ health; however Fit2travel is the second to be commercially produced from Australia. Fit2travel was released in 2011 by GlaxoSmithKline (GSK), Australia. Version 1.0 remains the downloadable version, as of this review, and it is unclear if there have been any updates, since it was released by GSK on 6 April 2011. The first travellers’ health application was Travel Health-English by Australian travel health practitioner, Dr Deborah Mills. This app was based on her popular book for travellers, Travelling Well, and Travel Health has been available since 2010 for a small fee and is periodically updated; currently Version 1.5. The Fit2travel application however has a different approach to the Travel Health application. The first major difference to Travel Health is that Fit2travel is a free download. The scope of information provided concentrates on providing the basics in travellers’ health without being overly comprehensive. It is also vaccination-centric, which is reinforced by GSK Australia’s supporting website and the link to a “Vaccination Reminder” service for travellers.Fit2travelPeter A. Leggat10.1016/j.tmaid.2012.02.001Travel Medicine and Infectious Disease 10, 2 (2012)2012-03-01Travel Medicine and Infectious Disease2012-03-01102S1477-8939(12)X0003-6Book Review105107